Cited by 20Retinal Diseases and TreatmentsRetinal Development and DisordersComplement system in diseases

Complement factor B is critical for sub-RPE deposit accumulation in a model of Doyne honeycomb retinal dystrophy with features of age-related macular degeneration

Open access
Crowley, Maura A, Garland, Donita L, Sellner, Holger, Banks, Angela, Fan, Lin, Rejtar, Tomas, Buchanan, Natasha, Delgado, Omar +15 more·2023·Human Molecular Genetics

Abstract

EFEMP1 R345W is a dominant mutation causing Doyne honeycomb retinal dystrophy/malattia leventinese (DHRD/ML), a rare blinding disease with clinical pathology similar to age-related macular degeneration (AMD). Aged Efemp1 R345W/R345W knock-in mice (Efemp1ki/ki) develop microscopic deposits on the basal side of retinal pigment epithelial cells (RPE), an early feature in DHRD/ML and AMD. Here, we assessed the role of alternative complement pathway component factor B (FB) in the formation of these deposits. RNA-seq analysis of the posterior eyecups revealed increased unfolded protein response, decreased mitochondrial function in the neural retina (by 3 months of age) and increased inflammatory pathways in both neural retina and posterior eyecups (at 17 months of age) of Efemp1ki/ki mice compared with wild-type littermate controls. Proteomics analysis of eye lysates confirmed similar dysregulated pathways as detected by RNA-seq. Complement activation was increased in aged Efemp1ki/ki eyes with an approximately 2-fold elevation of complement breakdown products iC3b and Ba (P < 0.05). Deletion of the Cfb gene in female Efemp1ki/ki mice partially normalized the above dysregulated biological pathway changes and oral dosing of a small molecule FB inhibitor from 10 to 12 months of age reduced sub-RPE deposits by 65% (P = 0.029). In contrast, male Efemp1ki/ki mice had fewer sub-RPE deposits than age-matched females, no elevation of ocular complement activation and no effect of FB inhibition on sub-RPE deposits. The effects of FB deletion or inhibition on Efemp1ki/ki mice supports systemic inhibition of the alternative complement pathway as a potential treatment of dry AMD and DHRD/ML.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddac187

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Crowley, M. A., Garland, D. L., Sellner, H., Banks, A., Fan, L., Rejtar, T., Buchanan, N., Delgado, O., Xu, Y. Y., Jose, S., Adams, C. M., Mogi, M., Wang, K., Bigelow, C. E., Poor, S., Anderson, K., Jaffee, B. D., Prasanna, G., Grosskreutz, C., Fernandez-Godino, R., Pierce, E. A., Dryja, T. P., & Liao, S.-M.
Affiliations
  • Ophthalmology, Novartis Institutes for BioMedical Research , Cambridge, MA 02319 , USA
  • Massachusetts Eye and Ear Infirmary (US)
  • Novartis (Switzerland) (CH)
  • Analytical Sciences and Imaging, Novartis Institutes for BioMedical Research , Cambridge, MA 02319 , USA
  • Global Discovery Chemistry, Novartis Institutes for BioMedical Research , Cambridge, MA 02319 , USA
  • Ocular Genomics Institute at Massachusetts Eye and Ear, Harvard Medical School , Boston, MA 02114 , USA
Corresponding author
Liao, Sha-Mei
Venue
Human Molecular Genetics
Published
2022-08-09
Volume
32
Issue
2
Pages
204-217
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W4290793038
Cited by
20
References
58
Citations by year
2026: 6 · 2025: 5 · 2024: 7 · 2023: 2
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Novartis Institutes for BioMedical Research
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
Keywords
Malattia Leventinese, factor B, alternative complement pathway, age-related macular degeneration, dry age-related macular degeneration, retinal pigment epithelium, unfolded protein response, mitochondrial dysfunction, ocular inflammation, complement activation, iC3b, BA, complement inhibitors, sex differences, knock-in mice
MeSH terms
Animals, Female, Macular Degeneration, Male, Complement Factor B, Retina, Optic Disk Drusen, Mice, Retinal Pigment Epithelium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review